Physician profile
Shermita Mitchell
NPI 1447865191
$4,853.31
in general payments reported to CMS, 2019-2025
18 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $217 · 2023: $611 · 2024: $1,879 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,635.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,059.71 | 2024-2025 | |
| Alcon Vision LLC | $815.36 | 2023-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Abbvie INC. | $586.00 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $433.73 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Mallinckrodt Hospital Products INC. | $395.75 | 2024-2025 | Acthar |
| Dompe US, INC. | $286.43 | 2024-2025 | Oxervate |
| Glaukos Corporation | $251.08 | 2023-2025 | Idose, Photrexa Viscous and Photrexa, Kxl1b-Ce-Marked Kxlsystem |
| Eyepoint US, INC. | $155.31 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $149.68 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $119.66 | 2024-2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $117.51 | 2024 | |
| Amgen INC. | $102.76 | 2025 | Tepezza |
| Allergan, INC. | $97.25 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $86.33 | 2024 | Tecnis Iol |
| Thea Pharma INC. | $73.46 | 2023-2025 | Iyuzeh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $57.11 | 2023-2024 | Syfovre |
| Harrow Eye, LLC | $45.24 | 2023 | Iheezo |
| Coherus Oncology, INC. | $20.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shermita Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.